Clinical trial
Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer…
NCT00374868 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00374868 |
|---|---|
| Title | Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable) |
| Official title | Phase 1/2 Study of Biweekly ALIMTA Plus Cisplatin in Patients With Locally, Advanced, Non-Resectable or Metastatic Urothelial Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Urologic Neoplasms |
| Intervention type | Drug |
| Interventions | pemetrexed, cisplatin |
| Enrollment | 59 |
| Start date | Aug 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Sep 12, 2006 |
| Last update posted | Nov 4, 2010 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: